INTRODUCTION
Multiple genome wide expression studies of sarcoidosis affected tissues have been published in the last 11 years. Published studies focused on differences in gene expression between sarcoidosis vs. control tissues, stable vs. progressive sarcoidosis, as well as sarcoidosis vs. other granulomatous and nongranulomatous diseases [1] [2] [3] [4] .
Understanding the transcriptome of tissues that are directly affected by the presence of granulomas, such as lung and skin, or of fluids in contact with granulomas, such as bronchoalveolar lavage (BAL) and peripheral blood, is of great importance to understand the biology of sarcoidosis. The signal of all transcripts and the majority of small and long noncoding RNA in humans can be detected by one microarray or RNA-Seq run, and then submitted to analysis that allows the understanding of intratissues and intertissues gene networks that underlie the biology of sarcoidosis.
Published transcriptomics studies indicate that numerous specific genes and signaling pathways implicated in inflammatory and immune T cells and macrophage responses differentiate sarcoidosis from control tissues and other diseased tissues. Specific and common gene expressions, miRNAs and pathways were identified in peripheral blood, BAL, and whole lung, orbital and lacrimal tissues lysate.
THE TRANSCRIPTOME OF SARCOIDOSIS IN DISEASE-AFFECTED TISSUES
Crouser et al. [5] used frozen lung tissues and detected 319 differentially expressed genes between sarcoidosis and control lungs (Table 1) [1] [2] [3] [4] [5] [6] 7 & ,8 & , 9 -13] . Functional analysis revealed genes implicated in cell movement, immune function and Th1 response [e.g. signal transducer and activator of transcription 1 (STAT1), interleukin (IL)-5, IL-7, IL-15, C-C chemokine receptor type 5 (CCR5) and chemokine (C-X-C motif) ligand 9 (CXCL9)] [5] . Newly identified MMP12 and ADAMDEC1, gene and protein expression, were significantly positively correlated with sarcoidosis severity in lung tissue and BAL [5] . In addition to analyzing gene profiles in lungs, Crouser et al. [6] identified 60 miRNA [false discovery rate (FDR) < 5%] in lungs and 214 miRNA (FDR < 5%) in peripheral blood mononuclear cells (PBMC), as differentially expressed between active pulmonary sarcoidosis and control. Although neither a significant overlap in miRNA expression nor of their chromosomal location was found between lung and PBMC, predicted targets of differentially expressed mRNA were commonly linked to transforming growth factor beta (TGF-b) and WNT regulated pathways. These findings support the notion that cell profiles of lung tissues and blood are very different, but at the same time are implicated in same pathways that are known to provide links between innate and adaptive immunity [14] [15] [16] , fibroproliferation [17] [18] [19] , granuloma formation and resolution [19, 20] . Limitations of the study included small numbers of tissues ( Table 1) that allowed for limited detection of significant differentially expressed mRNA and miRNA and the lack of a mechanism that proves the role of miRNA and their targets in TGF-b and WNT pathways in the context of sarcoidosis development and pulmonary outcome.
Rosenbaum et al. [21] analyzed gene expression profiles of unpaired lung, lymph nodes and peripheral blood from patients with sarcoidosis vs. controls. In line with the previously mentioned data, the authors also noticed a strong Th1 immune response, as well as STAT1 and three STAT1 regulated chemokines (CXCL9, CXCL10 and CXCL11) to be commonly upregulated in sarcoidosis [21] . STAT1 was already shown to be a key inflammatory and interferon (IFN)-g response transcription factor [22, 23] .
Lockstone et al. [1] compared the transcriptome of lung tissues of self-limiting vs. progressive-fibrotic sarcoidosis patients. Three hundred and thirty-four genes (P < 0.01) were found to be differentially expressed (Table 1) , suggesting immune response genes as drivers of fibrotic process in sarcoidosis rather than fibrogenic group of genes characteristic for idiopathic pulmonary fibrosis (IPF) [24] . However, the findings of this study were based on small sample size, lacking statistical power.
Judson et al. [25] performed a microarray analysis comparing the gene expression in skin tissue from 15 patients with active cutaneous sarcoidosis to five healthy controls. Ingenuity pathway analysis revealed that IFN signaling (type I and II) and the Th17 pathway, including IL-23, IL-23R and IL-21, are significantly dysregulated, however, with a limited expression of some hallmark Th17 pathway genes, like IL-17 itself.
Rosenbaum et al. [7 & ] established gene expressions profiles of orbital tissues and peripheral blood from 12 patients with sarcoidosis and six healthy controls with 125 genes being significantly differentially expressed in both orbital tissues and peripheral blood. Upregulated genes included CXCL10, GBP5, STAT1, AIM2, ICAM1 and JAK2, and were modulated by IFN-g and type I IFNs. Accordingly, enrichment analysis of transcription factor binding sites established that the transcription factors
KEY POINTS
Genome-wide expression studies of sarcoidosis affected tissues reveal novel gene profiles underlying the biology of sarcoidosis.
In the last 11 years, several genome-wide expression studies comparing sarcoidosis vs. control tissues, stable vs. progressive sarcoidosis, as well as sarcoidosis vs. other diseases were published.
Most transcriptomic studies confirm a key role of TH1 immune response in sarcoidosis, particularly of IFN-g and type I IFN-driven signaling pathways.
Although present transcriptomic studies mainly focus on identifying differences between sarcoidosis and control tissues, large prospective follow-up studies, time course sampling and single cell analysis focusing on the sickest patients are critically needed to identify signatures predictive of disease progression and outcome.
IFN-response factor 1 and 2, as well as nuclear factor kB, are involved in the transcriptional modulation in sarcoidosis.
THE BAL CELL TRANSCRIPTOME

Gharib et al. [8
& ] identified over 1500 differentially expressed genes when BAL cell gene expression was compared between sarcoidosis and healthy individuals (Table 1) . Gene set enrichment analysis of those genes revealed pathways associated with adaptive immune system, T-cell signaling (Th and CD8þ) and IFN-g, IL-12, IL-17 and IL-23 signaling, and identified a novel gene network linkage between immunoproteasome subunits (PSMB-8, PSMB-9 and PSMB-10). Barna et al. [9] performed another BAL cells gene expression microarray study and found Twist1 to be upregulated, among many macrophage M1 -characteristic genes (e.g. IFN-g, CCL5 and CXCL9), in sarcoidosis patients compared to controls. Furthermore, Twist1 protein was proposed to serve as a biomarker of M1, but not M2-activation (Table 1 ). The same group performed microarray analysis on BAL samples from severe (requiring systemic treatment) vs. nonsevere (never requiring treatment) stage of sarcoidosis [10] . Reduced expression of Cathelicidin (CAMP) mRNA was observed in severe sarcoidosis stage, and experimental findings suggested that TNF mediates repression of steroid receptor coactivator-3 and contributes to CAMP deficiency, which further may impede resolution of inflammation [10] . Comparison of BAL cells from patients with progressive and stable sarcoidosis by microarrays demonstrated increased expression of protein kinase TYK2 and cell cycle inhibitor p21Waf1/Cip1 genes, confirming the association of BAL cells with Th1 and IFN-g immune responses [11] .
THE PERIPHERAL BLOOD TRANSCRIPTOME IN SARCOIDOSIS
Several studies looked into differentially expressed genes in peripheral blood samples from healthy Whole blood gene expression signature distinguished sarcoidosis from healthy controls in UCSF and Oregon cohorts with an error rate of 12.1% (92% sensitivity and 92% specificity) [13] . Thirtyeight genes were found concordant between blood signature and lung biopsies in sarcoidosis vs. healthy controls [5, 13] . These genes belonged to Th1-type inflammation, such as IFN signaling pathway (IFN-a, IFN-b, IFN-g and STAT1) , and T-cell homeostasis and survival (IL-15 and IL-7R). Twenty-one genes were found to be concordant between the blood signature and lung biopsies classified as progressive vs. self-limiting sarcoidosis [1, 13] . This study suggests that blood transcriptional profile reflects lung transcriptional profile in sarcoidosis especially in specific inflammatory pathways.
Monast et al. [26 & ] analyzed the gene expression of whole blood samples of skin and lung sarcoidosis patients (n ¼ 164) participating in a large clinical trial of golimumab and ustekinumab in sarcoidosis (NCT00955279 [27] ), and of healthy controls (n ¼ 45). They identified a core signature of 497 genes differentiating from healthy controls, which was shared by all three phenotypes (skin, lung, and skin and lung combined). Pathway analysis revealed that the T-cell receptor (TCR) signaling was downregulated in each phenotype compared to healthy controls, potentially due to peripheral T-cell lymphopenia. Interestingly, the IFN signaling (type I and II) pathway was more upregulated in the combined lung and skin phenotype than in the skin phenotype, whereas no change in pathway regulation in the lung phenotype was observed.
SARCOIDOSIS-SPECIFIC GENE SIGNATURE
Both sarcoidosis and TB share the pathological hallmark of granuloma, being caseating in TB opposed to noncaseating epithelioid in sarcoidosis. Bloom et al. [4] compared the whole blood transcriptional profiles of sarcoidosis with tuberculosis (TB) and found that whole blood transcriptional profiles of sarcoidosis were similar to TB, and associated with IFN signaling (type I and II) and immune response pathways, but distinct from pneumonia and lung cancer that are mostly associated with inflammatory pathways. Gene expression from active sarcoidosis clustered with TB, whereas nonactive sarcoidosis clustered with controls. Significant increase in transcriptional activity and production of more inflammatory transcripts were seen in sarcoidosis patients who respond to glucocorticoid therapy. Type I IFNinducible genes were most abundant in neutrophils than in monocytes (CD14 þ ), and finally in lymphocytes (CD4 þ T cells and CD8 þ T cells). A signature of 144 transcripts was developed using class prediction methods and performed with more than 80% sensitivity and more than 90% specificity to distinguish TB from sarcoidosis, healthy controls, cancer and pneumonia. Although this signature performed well on the cohort from Maertzdorf et al. [2] , the 100 and 50 gene signatures, proposed to distinguish TB and sarcoidosis by Maertzdorf et al. [2] , and Koth et al. [13] , performed with much lower sensitivity (50-70%) and specificity (>87%) when tested on the Bloom et al. [4] cohort. Although there were only a few overlapping transcripts between the three mentioned gene signatures, the discrepancy can be explained by the small size of cohorts, the difference in the patients and other technical issues [4] .
Two research groups, Koth et al. [13] and Maertzdorf et al. [2] , independently explored the gene expression in peripheral blood in TB and sarcoidosis. Maertzdorf et al. [2] compared peripheral blood cell transcriptomes and miRNA expression in 18 healthy, IFN-g release assay-negative controls, 8 patients with active TB and 18 patients with sarcoidosis. Compared to healthy controls, gene expression in TB and sarcoidosis patients overlapped in 9045 genes. Both diseases showed an upregulation of IFN-signaling (type I and II) and IFN-inducible genes. Further common pathways were systemic lupus erythematosus, complement and coagulation cascades, toll-like receptor (TLR) signaling, Fc-g-receptor-mediated phagocytosis and even a TB pathway. Gene expression in sarcoidosis and TB differed only in 691 genes.
Koth et al. [13] analyzed gene expression of 20 healthy controls and 38 patients with sarcoidosis. As an additional comparator, two publicly available data sets composed of gene expression of TB patients were utilized. The top 50 genes discriminating sarcoidosis and healthy controls showed an impressive overlap to active TB gene expression pattern with DHRS9 and CCR7 having the most indistinguishable expression pattern. Using a gene module strategy, Koth et al. found a profound overlap of activated IFN pathways (type I and II) in sarcoidosis and TB. Thus, TB and sarcoidosis show an enormous transcriptional overlap with the huge majority of genes being concordantly regulated. Notably, lymphocyte-derived genes are commonly expressed such as IFN-signaling and IFN-inducible genes, suggesting a shared transcriptional programme. In TB, but not in sarcoidosis, elevated expression of genes involved in microbiological host defense and other neutrophil-specific genes was observed.
PERIPHERAL BLOOD TRANSCRIPTOME AND DISEASE OUTCOME Only one study used cross-sectional derivation transcriptomics data together with a longitudinal cohort to follow sarcoidosis disease outcome [28] . Lymphopenia and genes from IFN-signaling (STAT1, STAT2 and GBP1), pattern recognition (TLR2, TLR4 and TLR8) and T-cell receptors (CD28, ITK and LEF1), and CXCL9 initially identified in derivation cohort (whole blood), were analyzed for the capacity to predict and track sarcoidosis outcome longitudinally. TCR genes and CXCL9 outperformed lymphopenia in discriminating chronic vs. nonprogressive patients within sarcoidosis individuals who enrolled early in their disease course or were not on immunosuppression.
CONCLUSION
Transcriptomic studies have identified large numbers of differentially expressed genes and pathways distinguishing sarcoidosis patients from healthy controls and from patients with other diseases. Interpreting the interactome of mRNA and miRNA, including in silico modeling, led to the identification of immune and inflammatory pathways relevant for blood and BAL cells activation, granuloma formation and correlation with disease severity [2, 6, 29 ] . Impressively, all these transcriptomic data confirm the key role of IFN-g-driven STAT1 signaling as well as type I IFN signaling in sarcoidosis. The main limitations of most of the published transcriptomics studies are limited sample size, less than 20 patients in most studies, the lack of African Americans participants, the absence of time course data, and the use of cellular admixtures as input samples. The recently completed Genomics Research in Alpha-1 Antitrypsin and Sarcoidosis (GRADS) study used a multi 'omics' approach in analysis of three compartments (blood, BAL and stool), and included a large sample size with multiethnic participants, and proteomics, metabolomics and microbiomics but did not include prospective time course analysis and cellular subpopulations [30 & ] . Thus, future studies should include cutting-edge technologies that identify changes in specific cell subpopulations, potentially at the level of the single cells, and should provide prospective follow-up and repeated sampling to address disease dynamics and heterogeneity.
